Real‐world treatment trajectories preceding <scp>GLP</scp> ‐1 receptor agonist initiation in type 2 diabetes: A descriptive <scp>UK</scp> population‐based cohort study on adherence to national clinical guidelines
GLP-1RAs were predominantly initiated following ≥3 glucose-lowering agents, consistent with contemporary UK guidance (NG28). Post-2018, most GLP-1RA initiators received SGLT-2is concomitantly. However, CVD history did not influence prescribing patterns, underscoring missed opportunities to optimise the prevention of cardiovascular events and slow the progression of CVD.
Authors
- NICOLA NAPOLI
- Andrea M. Burden (ORCID: https://orcid.org/0000-0001-7082-8530)
- Morten Frost Nielsen
- Franziska Sophie Ulrich
Institutions
- Università Campus Bio-Medico (IT)
- Washington University in St. Louis (US)
- Odense University Hospital (DK)
- University of Alabama at Birmingham (US)
- ETH Zurich (CH)
- Campus Bio Medico University Hospital (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1111/dom.70548
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00